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Abstract
Background: Osteopontin (OPN) overexpression is correlated with a poor prognosis for tumor patients. However,
only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.
Methods: This study is based on tumor and serum samples from 93 adult STS patients. We investigated OPN
protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68)
by quantitative real-time PCR.
Results: No correlation was found between OPN levels in serum and tumor tissue. Moreover, an elevated OPN
protein level in the serum was significantly associated with clinical parameters such as higher stage (p = 0.004),
higher grade (p = 0.003), subtype (p = 0.002) and larger tumor size (p = 0.03). OPN protein levels in the tumor
tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased
rate of relapse (p = 0.02). In addition, using a Cox’s proportional hazards regression model, we found that an
elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for
patients with STS. The relative risks of tumor-related death were 2.2 (p < 0.05) and 3.7 (p = 0.01), respectively.
Conclusion: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic
factor for soft tissue sarcoma patients.
Background
OPN, a phosphorylated glycoprotein, is detected in body
fluids as well as in tumor tissues. Initially, it was sug-
gested that OPN is expressed by macrophages infiltrat-
ing the tumor rather than by tumor cells themselves [1].
However, elevated serum or plasma levels of OPN have
been detected in a variety of human cancers, which has
been correlated with tumor progression and metastasis
[2-4]. Moreover, tumor OPN protein over expression is
also linked to a worse prognosis in different tumor enti-
ties such as breast cancer [5,6], lung cancer [7], cervical
cancer [8,9], prostate cancer [10] and head and neck
cancer [11-13]. Furthermore, previous studies suggest
that high tumor OPN mRNA expression also correlates
with an unfavorable prognosis [14-18].
In support of its prognostic value, direct or indirect
inhibition of the OPN signaling pathway results in
reduced malignant tumor potential with effects on cell
survival, migration, invasion, tumor growth and metasta-
sis (reviewed in [4,19,20]). However, only a few studies
have investigated the role of osteopontin in tumor pro-
gression of sarcoma patients. For example, in primary
sarcomas of the pulmonary artery, OPN protein could
be detected in tumor cells and in macrophages and it is
potentially involved in tumor progression and metastasis
[21]. A further immunohistochemical study of STS
showed that OPN in tumor tissue is associated with
tumor stage, grade and overall survival of STS patients
at 5-years [22]. However, another study using immuno-
histochemical evaluation of OPN expression did not
provide predictive information on the outcome of osteo-
sarcoma patients [23]. We therefore analyzed OPN
mRNA and protein levels of tumor samples and OPN
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patients. Moreover, to characterize the role of OPN in
soft tissue sarcoma, we correlated OPN levels with clini-
cal parameters and prognosis.
Methods
Patients and tumor material
Tumor tissue and serum samples of 93 adult patients
with histologically verified primary STS were analyzed
(Table 1). In detail, we have analyzed OPN protein
levels in serum (86 patients) and tumor tissue (80
patients) and OPN mRNA level in tumor tissue (68
patients). Patients and tissue samples have been partially
described previously [24-26]. The study was carried out
in compliance with the Helsinki Declaration and it was
approved by the Ethics Committee of the Medical
Faculty of the University Halle. All patients gave written
informed consent (Institute of Pathology, University of
Halle, Germany and Department of Surgery 1, Univer-
sity of Leipzig, Germany). Patients’ mean age was 56
years (19 to 87 years). The median follow-up time was
44 months (2 to 146 months). The overall survival
according to stage was 86% for stage I (n = 15), 59% for
stage II (n = 39), 37% for stage III (n = 19) and 0% for
stage IVa (n = 9). Tumor tissue was collected following
surgical resection and snap-frozen in liquid nitrogen.
Tumors were classified according to the van Unnik
grading system [27].
Reverse transcription-polymerase chain reaction and real-
time quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit
according to the manufacturer’s instructions (Qiagen,
Hilden, Germany). Subsequently, 1000 ng of RNA was
reverse transcribed with random hexamer primers and
Superscript II reverse transcriptase (Invitrogen,
Table 1 Histopathological and clinical data in soft tissue sarcoma patients
Serum OPN protein Tumor OPN protein Tumor OPN mRNA
Total 86 80 68
Tumor stage
I1 41 31 2
II 37 32 26
III 26 26 22
IV 9 9 8
Tumor type
LS 21 21 18
FS and MFH 24 20 17
NS 8 7 3
RMS and LMS 22 22 20
Other STS 11 10 10
Irradiation
Yes 31 32 29
No 55 48 39
Chemotherapy
Yes 8 7 5
No 78 73 63
Tumor size
T1 12 11 10
T2 74 69 58
Tumor resection
Radical (R0) 57 54 49
Not Radical (R1) 29 26 19
Distant metastases
M0 79 73 62
M1 7 7 6
Relapse
Yes 55 51 47
No 31 29 21
Abbreviations: OPN: osteopontin, LS: liposarcoma, MFH: malignant fibrous histiocytoma; FS: fibrosarcoma; NS: neurogenic sarcoma; LMS: leiomyosarcoma; RMS:
rhabdomyosarcoma; STS: soft tissue sarcoma;
Bache et al. BMC Cancer 2010, 10:132
http://www.biomedcentral.com/1471-2407/10/132
Page 2 of 8Karlsruhe, Germany). The cDNA synthesis was per-
formed as described previously [28]. The mRNA levels
of OPN and the housekeeping gene, hypoxanthin phos-
phoribosyl-transferase (HPRT), were quantified using
Quantitect SYBRGreen PCR kit (Qiagen, Hilden, Ger-
many) in a Rotorgene 3000 thermal cycler (LTF Labor-
technik, Wasserburg, Germany). The OPN and HPRT
transcripts were amplified with primer pairs of Table 2.
The PCR cycling conditions included incubation for 15
min at 95°C, followed by 40 cycles of 30 sec at 95°C, 30
sec at 60°C and 30 sec at 72°C. A melting curve analysis
in a range from 65°C to 95°C (5°C/sec) was appended.
OPN mRNA was quantified as molecules of OPN
mRNA/pg HPRT mRNA.
OPN-ELISA measurements
Tumor tissue extracts were prepared from frozen tissues
using a standard extraction protocol. Briefly, 20 slices of
10 μm thickness were cut. The total protein was
extracted by solubilizing the tissues in 1 ml Giordano
buffer using sonication on ice. The cell lysates were clar-
ified by centrifugation at 15000 rpm for 15 min. The
protein content was determined using the Bradford
assay. Fresh blood samples collected before surgical
treatment were coagulated for 20 min at room tempera-
ture and centrifuged at 3000 rpm for 10 min (Sarstedt
monovette, Nümbrecht, Germany). The serum and
tumor tissue extracts were aliquoted and stored at -80°C
until analysis. Aliquots of each sample were analyzed in
duplicate using a commercial ELISA system for OPN
(IBL International, Hamburg, Germany) according to
the manufacturer’s instructions [3].
Statistical methods
All statistical analyses were performed with the SPSS
software package 16.0 for Windows (SPSS Inc., Chicago,
IL). The differences in the numerical data between two
groups were evaluated using the Pearson’st e s to rF i s h -
er’s exact test. For survival analyses the overall survival
of STS patients was used as follow-up end point. The
survival curves were generated using Kaplan-Meier ana-
lysis and the log rank test was used to test for differ-
ences. For univariate and multivariate analyses (adjusted
to tumor stage) the Cox’s proportional hazard regression
model was used to calculate the hazard ratio in the
analysis of survival. A p-value of less than 0.05 was con-
sidered to be statistically significant.
Results
Osteopontin levels in serum and tumor tissue
In patients with soft tissue sarcoma (STS) the median
protein concentration of OPN in the serum and tumor
tissue extracts was 704 ng/ml (184-2660 ng/ml) and
51.9 ng/mg (3.2-868 ng/mg), respectively (Fig. 1). The
median OPN/HPRT transcript level ratio was 12.8 mole-
cules OPN/pg HPRT (with a range of 0-110 molecules
OPN/pg HPRT, Fig. 1). In particular, there was no cor-
relation between OPN mRNA and OPN protein levels
of tumors (n = 66; p = 0.4), serum and tumor OPN pro-
tein levels (n = 73; p = 0.9) or tumor OPN mRNA and
serum OPN protein levels (n = 62; p = 0.7).
Osteopontin levels and survival analyses
In subgroups split at the median serum or tumor OPN
protein level, there was no significant difference in over-
all survival. However, when specimens were divided into
four groups according to their OPN protein levels, the
serum and tumor OPN protein levels did associate with
different clinical parameters and overall survival. The
group with the lowest tumor (≤ 34.34 ng/mg) or serum
(≤ 516.54 ng/ml) OPN protein levels, i. e., the lowest
quartile, had a favorable outcome compared to the other
three groups (Table 3).
Kaplan-Meier analyses showed a significant decrease of
overall survival for the three groups with high OPN pro-
tein levels compared to the group with the lowest tumor
(p = 0.007; log-rank test) and serum (p = 0.04; log-rank
test) OPN protein levels. The mean survival time of the
patient group with the lowest OPN protein level was 103
months (serum) and 68 months (tumor) whereas patients
of the three remaining groups (high OPN protein levels)
survived on average 60 months and 58 months (for
serum and tumor tissue OPN protein levels, respectively).
In addition, patients with both high serum and high
tumor OPN protein levels had the worst prognosis (data
not shown). Using a univariate Cox regression hazard
model for STS patients with high OPN protein level in
the serum or in tumor tissue extracts, the risk of tumor-
related death was a 2.2 (95% confidence interval (CI)
1.01-5.1; p < 0.05) and 3.7 (95% confidence interval (CI)
1.3-10.4; p = 0.01), respectively (Fig. 2, Table 3). How-
ever, in a multivariate Cox’s regression hazard model
adjusted to tumor stage OPN protein level was not signif-
icantly correlated with prognosis.
Bivariate analysis of osteopontin levels with clinical
parameters
Bivariate analysis of OPN expression did show an asso-
ciation of serum and tumor OPN protein levels with
Table 2 Primer sequences and primer locations applied
for qRT-PCR
gene primer sequence 5’ ! 3’ Localization
HPRT sense 5’-TTGCTGACCTGCTGGATTAC-3’ 309-328
antisense 5’-CTTGCGACCTTGACCATCTT-3’ 551-570
OPN sense 5’-TGGCCGAGGTGATAGTGTG-3’ 555-573
antisense 5’-CGGGGATGGCCTTGTATG-3’ 686-703
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OPN protein levels correlated with high tumor stage (p
= 0.004), grade of tumors (p = 0.003) and tumor size (p
= 0.03). Additionally, all patients with early distant
metastasis (7/86) had a high median serum OPN protein
level of 1301 ng/ml (1009 to 2660 ng/ml) compared to
patients without distant metastasis (79/86) who had a
median serum OPN protein level of 657 ng/ml (183 to
1873 ng/ml). However, the difference was not significant
(Table 3). A high tumor OPN protein level was signifi-
c a n t l yr e l a t e dt ot u m o rg r a d e( p=0 . 0 0 3 )a n da n
increased rate of relapse (p = 0.02), and also showed a
trend association with high tumor stage (p = 0.06)
(Table 3). Furthermore, plasma OPN protein levels sig-
nificantly correlated with tumor type (p = 0.002)
whereas tumor OPN protein levels displayed only a
trend association with tumor type (p = 0.07). Moreover,
the patient group with the lowest serum and tumor
OPN protein level was composed of 57% and 48% lipo-
sarcoma patients, respectively. In contrast, the three
remaining patient groups with a high serum (>516.54
ng/ml) and tumor (>34.34 ng/mg) OPN protein level
were composed of more than 80% of patients with
malignant fibrous histiocytoma (MFH), fibrosarcoma
(FS), leiomyosarcoma (LMS), rhabdomyosarcoma
(RMS). In contrast to protein expression, statistical ana-
lysis of OPN mRNA levels showed no association with
clinical parameters or clinical outcome (Table 3).
Discussion
OPN overexpression is linked to an unfavorable prog-
nosis in a variety of human cancers. However, only a
few studies to date have investigated the prognostic
impact of osteopontin in sarcoma patients. In the pre-
sent study, we analyzed OPN mRNA and protein levels
in tumors and the OPN protein levels from the serum
of 93 soft tissue sarcoma patients and correlated OPN
levels with clinical parameters and prognosis.
In our study no correlation was found between OPN
levels in serum and tumor tissue. It is well known that
extracellular OPN is involved to tumor progression with
signaling to proliferation, migration and survival. Also
intracellular OPN is involved in cell migration [29].
Additionally, there is also evidence that suggests that
intracellular OPN has other cellular functions, particu-
larly in relation to cell proliferation [30]. But regulation
between intra- and extracellular OPN forms remains
unknown. Nordsmark et al. (2007) assume a relation
between plasma concentration of OPN and intratumoral
OPN production [31]. However, in agreement with our
Figure 1 OPN levels in serum and tumor tissue of STS patients.
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between plasma OPN and tumor OPN protein levels in
patients with head and neck cancer (p = 0.75). Further-
more, own in vitro studies detected a clear decrease of
extracellular OPN protein levels after transfection with
OPN siRNA in MDA-MB231 cells. In contrast, the
intracellular OPN protein level was only partially
decreased (Hahnel et al., manuscript submitted). More
studies on the functions of intracellular OPN forms are
necessary to understand their relationship with extracel-
lular OPN and their tumor biological role.
Our data suggest that increased serum and tumor
OPN protein levels are significantly associated with clin-
ical parameters, such as tumor stage, tumor grade, sub-
type of tumor, tumor size and the rate of relapse (Table
3). In the Kaplan-Meier analysis, a significantly
decreased overall survival was observed for patients with
strong OPN protein expression in their serum (p = 0.04;
Table 3) and tumor tissue (p = 0.007; Table 3). Further-
more, the univariate Cox’s regression hazard model
demonstrated that STS patients with a high serum and
tumor OPN protein level have an increased risk of
tumor-related death of 2.2 (p < 0.05) and 3.7 (p = 0.01;
Fig. 2), respectively (Table 3). This is in agreement with
a previously reported immunohistochemical study of 33
soft tissue sarcoma patients that showed an increased
OPN level significantly correlated with higher tumor
stage, grade and overall survival [22]. Furthermore, pri-
mary sarcomas of the pulmonary artery display an abun-
dant immunohistochemical OPN protein staining of
tumor cells and extracellular matrix. Therefore, OPN
protein may play a substantial role in tumor progression
of vessel sarcomas [21]. However, an immunohisto-
chemical OPN study did not find any correlation
Table 3 Association of serum and tumor OPN levels with clinical parameters in soft tissue sarcoma patients
Category Serum OPN protein level
in ng/ml
Tumor OPN protein level
in ng/mg
Tumor OPN mRNA level in
molecules/pg HPRT
≤ 516.54 >516.54 ≤ 34.34 >34.34 ≤ 0.576 >0.576
Total 21 65 20 60 17 51
Tumor stage p = 0.004* p = 0.06 p = 0.21
I8 6 7 6 5 7
II 10 27 7 25 7 19
III 2 24 4 22 5 17
IV 1 8 2 7 0 8
Tumor type p = 0.002* p = 0.07 p = 0.19
LS 12 9 10 11 5 13
FS+MFH 4 20 3 17 6 11
NS 0 8 2 5 2 1
RMS+LMS 3 19 4 18 3 17
Other STS 2 9 1 9 1 9
Tumor size p = 0.03* p = 0.85 p = 0.24
T1 6 6 3 8 1 9
T2 15 59 17 52 16 42
Distant metastasis p = 0.12 p = 0.82 p = 0.14
M0 21 58 18 55 17 45
M1 0 7 2 5 0 6
Relapse p = 0.41 p = 0.02* p = 0.88
R0 15 40 17 34 12 35
R1 6 25 3 26 5 16
Follow-up
Alive 14 29 16 21 11 23
Dead 7 36 4 39 6 28
Kaplan-Meier analysis p = 0.04* p = 0.007* p = 0.2
mean survival in months 103 60 68 58 72 65
Cox’s-Regression model p < 0.05* p = 0.01* p = 0.21
RR 2.2 3.7 1.7
CI 1.0-5.1 1.3-10.4 0.7-4.3
p* value was significant, when p < 0.05. Abbreviations: OPN: osteopontin, LS: liposarcoma, MFH: malignant fibrous histiocytoma; FS: fibrosarcoma; NS: neurogenic
sarcoma; LMS: leiomyosarcoma; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma; RR: relative risk of tumor-related death; CI: confidence interval of tumor-
related death.
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sarcoma patients [23]. In this regard, Luo et al. were
able to show that different osteosarcoma cell lines had
significantly lower OPN levels than mature osteoblasts
[32]. This may indicate that OPN has no significance for
osteosarcoma tumor growth. However, antisense oligo-
deoxynucleotides against human OPN reduced the
tumorigenicity of xenotransplanted osteosarcoma
tumors in nude mice [33]. Additionally, our analysis
shows that siRNA-induced osteopontin inhibition results
in reduced clonogenic survival and migration of soft tis-
sue sarcoma and breast cancer cell lines (Hahnel et al.,
manuscript submitted).
Our analysis of tumor OPN mRNA expression of 68
soft tissue sarcoma patients did not show any associa-
tion with clinical parameters or prognosis. In contrast,
another study of 41 osteosarcoma patients did show that
a high OPN mRNA level is correlative with overall sur-
vival, event-free survival and relapse-free survival [34].
Moreover, a study of 15 adult soft tissue sarcoma
patients showed a significant increase of OPN mRNA
levels compared to normal tissue [22]. In addition, OPN
splice variants may be involved in tumor progression. In
particular, osteopontin-c has been postulated to be a
significant factor for glioma [35], breast cancer [17,36]
and hepatocellular carcinoma [37]. Clearly, more data
are needed to characterize the role of osteopontin
mRNA in sarcomas.
Conclusion
In the present study, we analyzed OPN mRNA and pro-
tein levels in tumors and the OPN protein levels from
the serum of 93 soft tissue sarcoma patients. Our data
suggest that increased serum and tumor OPN protein
levels are significantly associated with clinical para-
meters, such as tumor stage, tumor grade, subtype of
tumor, tumor size and the rate of relapse. In addition,
using a univariate Cox’s proportional hazards regression
model, we found that an elevated OPN protein level in
the serum and tumor tissue extracts is a significant
negative prognostic factor for patients with STS. Our
data suggest OPN protein in serum as well as in tumor
tissue extracts is an important prognostic factor for soft
tissue sarcoma patients.
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